Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction

Neurobiology of Disease

Volumn 24, Issue 2, 2006, Pages 403-418

  Dierssen, Mara ^a,f   Gratacòs, Mònica ^a,f   Sahún, Ignasi ^a,f   Martín, Miguel ^b,f   Gallego, Xavier ^a,f   Amador Arjona, Alejandro ^a,f   Martínez de Lagrán, María ^a,f   Murtra, Patricia ^b,f   Martí, Eulalia ^a,f   Pujana, Miguel A ^a,f   Ferrer, Isidre ^c,f   Dalfó, Esther ^c,f   Martínez Cué, Carmen ^d,f   Flórez, Jesús ^d,f   Torres Peraza, Jesús F ^e,f   Alberch, Jordi ^e,f   Maldonado, Rafael ^b,f   Fillat, Cristina ^a,f   Estivill, Xavier ^a,f  

^a Barcelona Biomedical Research Park   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Anxiety like behavior; Locus coeruleus; Mouse defense test battery; NT 3; Panic disorder; TrkC

Indexed keywords

CATECHOLAMINE; DIAZEPAM; NEUROTROPHIN 3 RECEPTOR; NEUROTROPHIN RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BRAIN REGION; CATECHOLAMINE NERVE CELL; CELL DENSITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FEMALE; LOCUS CERULEUS; MALE; MAZE TEST; MOUSE; NONHUMAN; NORADRENERGIC NERVE; PANIC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

ANIMALS; ANXIETY DISORDERS; AUTONOMIC NERVOUS SYSTEM DISEASES; BEHAVIOR, ANIMAL; BRAIN; CATECHOLAMINES; CELL COUNT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; LOCUS COERULEUS; MALE; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE; PANIC DISORDER; RECEPTOR, TRKC; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 33750126424     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.07.015     Document Type: Article

References (80)

1. Akbarian S., Bates B., Liu R.J., Skirboll S.L., Pejchal T., Coppola V., Sun L.D., Fan G., Kucera J., Wilson M.A., Tessarollo L., Kosofsky B.E., Taylor J.R., Bothwell M., Nestler E.J., Aghajanian G.K., and Jaenisch R. Neurotrophin-3 modulates noradrenergic neuron function and opiate withdrawal. Mol. Psychiatry 6 (2001) 593-604
2. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., and Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 10 (2001) 1915-1923
3. Arenas E., and Persson H. Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 367 (1994) 368-371
4. Arenas E., Trupp M., Akerud P., and Ibanez C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 15 (1995) 1465-1473
5. Aston-Jones G., Valentino R.J., Van Bockstaele E., and Meyerson A. In: Marburg M. (Ed). Locus Coeruleus, Stress, and PTSD: Neurobiological and Clinical Parallels (1996), American Psychiatric Press, Washington, DC 17-62
6. Baamonde C., Lumbreras M., Martínez-Cué C., Vallina I.F., García-Calatayud S., Flórez J., and Dierssen M. Acute effect of postnatal manipulation on central beta-adrenoceptor transmission. Stress 3 (1999) 147-162
7. Baamonde C., Lumbreras M.A., MartInez-Cue C., Vallina I.F., Florez J., and Dierssen M. Postnatal handling induces long-term modifications in central beta-noradrenergic signalling in rats. Stress 5 (2002) 137-147
8. Balaban C.D. Neural substrates linking balance control and anxiety. Physiol. Behav. 77 (2002) 469-475
9. Bandler R., and Shipley M.T. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?. Trends Neurosci. 17 (1994) 379-389
10. Belzung C., and Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56 (1994) 623-628
11. Blanchard R.J., Griebel G., Henrie J.A., and Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 21 (1997) 783-789
12. Blanchard D.C., Griebel G., and Blanchard R.J. Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci. Biobehav. Rev. 25 (2001) 205-218
13. Bremner J.D., Krystal J.H., Southwick S.M., and Charney D.S. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23 (1996) 28-38
14. Bremner J.D., Krystal J.H., Southwick S.M., and Charney D.S. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23 (1996) 39-51
15. Canals J.M., Marco S., Checa N., Michels A., Perez-Navarro E., Arenas E., and Alberch J. Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease. Neurobiol. Dis. 5 (1998) 357-364
16. Canals J.M., Checa N., Marco S., Michels A., Perez-Navarro E., and Alberch J. The neurotrophin receptors trkA, trkB and trkC are differentially regulated after excitotoxic lesion in rat striatum. Brain Res. Mol. Brain Res. 69 (1999) 242-248
17. Castren E. Neurotrophic effects of antidepressant drugs. Curr. Opin. Pharmacol. 4 (2004) 58-64
18. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol. Neurobiol. 29 (2004) 289-302
19. Charney D.S., Woods S.W., Nagy L.M., Southwick S.M., Krystal J.H., and Heninger G.R. Noradrenergic function in panic disorder. J. Clin. Psychiatry 51 (1990) 5-11
20. Chourbaji S., Hellweg R., Brandis D., Zörner B., Zacher C., Lang U.E., Henn F.A., Hörtnagl H., and Gass P. Mice with reduced brain-derived neurotrophic factor expression show decreased choline acetyltransferase activity, but regular brain monoamine levels and unaltered emotional behavior. Mol. Brain Res. 121 (2004) 28-36
21. Crawley J.N. What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice (2000), Wiley, New York
22. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., and Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berlin) 132 (1997) 107-124
23. Crowe R.R., Goedken R., Samuelson S., Wilson R., Nelson J., and Noyes Jr. R. Genomewide survey of panic disorder. Am. J. Med. Genet. 105 (2001) 105-109
24. Dierssen M., Fotaki V., Martínez de Lagrán M., Gratacòs M., Fillat C., and Estivill X. Neurobehavioral development of two mouse lines commonly used in transgenic studies. Pharmacol. Biochem. Behav. 73 (2002) 19-25
25. Ernfors P., Lee K.F., Kucera J., and Jaenisch R. Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents. Cell 77 (1994) 503-512
26. Escorihuela R.M., Fernández-Teruel A., Tobeña A., Vivas N.M., Mármol F., Badia A., and Dierssen M. Early environmental enrichment produces long lasting neurochemical changes on β-adrenoceptor transduction system. Neurobiol. Learn. Mem. 64 (1995) 49-57
27. Escorihuela R.M., Fernández-Teruel A., Vallina I.F., Baamonde C., Dierssen M., Tobeña A., and Flórez J. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 199 (1995) 143-146
28. Fallon J.H., and Loughlin S.E. Monoamine innervation of the forebrain: collateralization. Brain Res. Bull. 9 (1982) 295-307
29. Fariñas I., Jones K.R., Backus C., Wang X.Y., and Reichardt L.F. Severe sensory and sympathetic deficits in mice lacking neurotrophin-3. Nature 369 (1994) 658-661
30. Franklin K.B.J., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates (1997), Academic Press, San Diego
31. Friedman W.J., Ibanez C.F., Hallbook F., Persson H., Cain L.D., Dreyfus C.F., and Black I.B. Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp. Neurol. 119 (1993) 72-78
32. Goddard A.W., and Charney D.S. Toward an integrated neurobiology of panic disorder. J. Clin. Psychiatry 58 (1997) 4-11
33. Gratacos M., Nadal M., Martin-Santos R., Pujana M.A., Gago J., Peral B., Armengol L., Ponsa I., Miro R., Bulbena A., et al. A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 106 (2001) 367-379
34. Griebel G., Blanchard D.C., Jung A., Lee J.C., Masuda C.K., and Blanchard R.J. Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology 34 (1995) 1625-1633
35. Griebel G., Blanchard D.C., Agnes R.S., and Blanchard R.J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berlin) 120 (1995) 57-66
36. Griebel G., Blanchard D.C., and Blanchard R.J. Evidence that the behaviors in the mouse defense test battery relate to different emotional states: a factor analytic study. Physiol. Behav. 60 (1996) 1255-1260
37. Griebel G., Perrault G., and Sanger D.J. Differences in anxiolytic-like profile of two novel nonbenzodiazepine BZ (omega) receptor agonists on defensive behaviors of mice. Pharmacol. Biochem. Behav. 62 (1999) 689-694
38. Griebel G., Belzung C., and Perrault G. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148 (2000) 164-170
39. Gundersen H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147 (1987) 229-263
40. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149 (1998) 183-192
41. Holm P.C., Rodríguez F.J., Kresse A., Canals J.M., Silos-Santiago I., and Arenas E. Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 130 (2003) 3535-3545
42. Hoogendijk W.J., Freenstra M.G., Botterblom M.H., Gilhuis J., Sommer I.E., Kamphorst W., Eikelenboom P., and Swaab D.F. Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann. Neurol. 45 (1999) 82-91
43. Jones B.E. The role of noradrenergic locus-ceruleus neurons and neighboring cholinergic neurons of the pontomesencephalic tegmentum in sleep-wake states. Prog. Brain Res. 88 (1991) 533-543
44. Khachigian L.M., Fries J.W., Benz M.W., Bonthron D.T., and Collins T. Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells. J. Biol. Chem. 269 (1994) 22647-22656
45. King V.R., Michael G.J., Joshi R.K., and Priestley J.V. trkA, trkB, and trkC messenger RNA expression by bulbospinal cells of the rat. Neuroscience 92 (1999) 935-944
46. Knowles J.A., Fyer A.J., Vieland V.J., Weissman M.M., Hodge S.E., Heiman G.A., Haghighi F., de Jesus G.M., Rassnick H., Preud'homme-Rivelli X., et al. Results of a genome-wide genetic screen for panic disorder. Am. J. Med. Genet. 81 (1998) 139-147
47. Koponen E., Voikar V., Riekki R., Saarelainen T., Rauramaa T., Rauvala H., Taira T., and Castren E. Transgenic mice overexpressing the full-length neurotrophin receptor trkB exhibit increased activation of the trkB-PLCgamma pathway, reduced anxiety, and facilitated learning. Mol. Cell. Neurosci. 26 (2004) 166-181
48. Lamballe F., Smeyne R.J., and Barbacid M. Developmental expression of trkC, the neurotrophin-3 receptor, in the mammalian nervous system. J. Neurosci. 14 (1994) 14-28
49. Lin P.Y., and Tsai G. Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia. Schizophr. Res. 71 (2004) 353-360
50. Liu Q.R., Walther D., Drgon T., Polesskaya O., Lesnick T.G., Strain K.J., de Andrade M., Bower J.H., Maraganore D.M., and Uhl G.R. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134 (2005) 93-103
51. Loughlin S.E., Foote S.L., and Fallon J.H. Locus coeruleus projections to cortex: topography, morphology and collateralizations. Brain Res. Bull. 9 (1982) 287-294
52. Maccarrone M., Valverde O., Barbaccia M.L., Castañé A., Maldonado R., Ledent C., Parmentier M., and Finazzi-Agrò A. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. 15 (2002) 1178-1186
53. Maron E., Nikopensius T., Koks S., Altmae S., Heinaste E., Vabrit K., Tammekivi V., Hallast P., Koido K., Kurg A., Metspalu A., Vasar E., Vasar V., and Shlik J. Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatr. Genet. 15 (2005) 17-24
54. Martin-Iverson M.T., and Altar C.A. Spontaneous behaviours of rats are differentially affected by substantia nigra infusions of brain-derived neurotrophic factor and neurotrophin-3. Eur. J. Neurosci. 8 (1996) 1696-1706
55. Masuya H., Inoue M., Wada Y., Shimizu A., Nagano J., Kawai A., Inoue A., Kagami T., Hirayama T., Yamaga A., Kaneda H., Kobayashi K., Minowa O., Miura I., Gondo Y., Noda T., Wakana S., and Shiroishi T. Implementation of the modified-SHIRPA protocol for screening of dominant phenotypes in a large-scale ENU mutagenesis program. Mamm. Genome. 16 (2005) 829-837
56. Muragaki Y., Timothy N., Leight S., Hempstead B.L., Chao M.V., Trojanowski J.Q., and Lee V.M.Y. Expression of trk receptors in the developing and adult human central and peripheral nervous system. J. Comp. Neurol. 656 (1995) 387-397
57. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., et al. Preclinical models: status of basic research in depression. Biol. Psychiatry 52 (2002) 503-528
58. Nibuya M., Morinobu S., and Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15 (1995) 7539-7547
59. Numan S., and Seroogy K.B. Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study. J. Comp. Neurol. 403 (1999) 295-308
60. Numan S., Lane-Ladd S.B., Zhang L., Lundgren K.H., Russell D.S., Seroogy K.B., and Nestler E.J. Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal. J. Neurosci. 18 (1998) 10700-10708
61. Otto C., Martin M., Wolfer D.P., Lipp H.P., Maldonado R., and Schütz G. Altered emotional behaviour in PACAP-type-I-.receptor-deficient mice. Mol. Brain Res. 92 (2001) 78-84
62. Priolo E., Libri V., Lopilato R., David E., Nappi G., and Nistico G. Panic-like attack induced by microinfusion into the locus coeruleus of antagonists and inverse agonists at GABAA-receptors in rodents. Funct. Neurol. 6 (1991) 393-403
63. Reiriz J., Holm P.C., Alberch J., and Arenas E. BMP-2 and cAMP elevation confer locus coeruleus neurons responsiveness to multiple neurotrophic factors. J. Neurobiol. 50 (2002) 291-304
64. Resnick N., Collins T., Atkinson W., Bonthron D.T., Dewey Jr. C.F., and Gimbrone Jr. M.A. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 4591-4595
65. Ribases M., Gratacos M., Fernandez-Aranda F., Bellodi L., Boni C., Anderluh M., Cavallini M., Cellini E., Di Bella D., Erzegovesi S., Foulon C., Gabrovsek M., Gorwood P., Hebebrand J., Hinney A., Holliday J., Hu X., Karwautz A., Kipman A., Komel R., Nacmias B., Remschmidt H., Ricca V., Sorbi S., Tomori M., Wagner G., Treasure J., Collier D.A., and Estivill X. Association of BDNF with restricting anorexia nervosa and minimum body mass index: a family-based association study of eight European populations. Eur. J. Hum. Genet. 13 (2005) 428-434
66. Rios M., Fan G., Fekete C., Kelly J., Bates B., Kuehn R., Lechan R.M., and Jaenisch R. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol. Endocrinol. 15 (2001) 1748-1757
67. Saarelainen T., Hendolin P., Lucas G., Koponen E., Sairanen M., MacDonald E., Agerman K., Haapasalo A., Nawa H., Aloyz R., Ernfors P., and Castrén E. Activation of the trkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23 (2003) 349-357
68. Sashara M., Fries J.W., Raines E.W., Gown A.M., Westrum L.E., Frosch M.P., Bonthron D.T., Ross R., and Collins T. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 64 (1991) 217-227
69. Schumacher J., Jamra R.A., Becker T., Ohlraun S., Klopp N., Binder E.B., Schulze T.G., Deschner M., Schmal C., Hofels S., Zobel A., Illig T., Propping P., Holsboer F., Rietschel M., Nothen M.M., and Cichon S. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol. Psychiatry 58 (2005) 307-314
70. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., and Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22 (2002) 3251-3261
71. Sklair-Tavron L., and Nestler E.J. Opposing effects of morphine and the neurotrophins, NT3, NT-4, and BDNF, on locus coeruleus neurons in vitro. Brain Res. 702 (1995) 117-125
72. Smith M.A., Makino S., Altemus M., Michelson D., Hong S.K., Kvetnansky R., and Post R.M. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 8788-8792
73. Szot P., White S.S., Greenup J.L., Leverenz J.B., Peskind E.R., and Raskind M.A. Compensatory changes in the noradrenergic nervous system in the locus coeruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J. Neurosci. 26 (2006) 467-478
74. Tadokoro K., Hashimoto R., Tatsumi M., Kamijima K., and Kunugi H. Analysis of enhancer activity of a dinucleotide repeat polymorphism in the neurotrophin-3 gene and its association with bipolar disorder. Neuropsychobiol. 50 (2004) 206-210
75. Thorgeirsson T.E., Oskarsson H., Desnica N., Kostic J.P., Stefansson J.G., Kolbeinsson H., Lindal E., Gagunashvili N., Frigge M.L., Kong A., et al. Anxiety with panic disorder linked to chromosome 9q in Iceland. Am. J. Hum. Genet. 72 (2003) 1221-1230
76. Tolwani R.J., Buckmaster P.S., Varma S., Cosgaya J.M., Wu Y., Suri C., and Shooter E.M. BDNF overexpression increases dendrite complexity in hippocampal dentate gyrus. Neuroscience 114 (2002) 795-805
77. Tsoulfas P., Stephens R.M., Kaplan D.R., and Parada L.F. trkC isoforms with inserts in the kinase domain show impaired signaling responses. J. Biol. Chem. 271 (1996) 5691-5697
78. Weissman M.M., Fyer A.J., Haghighi F., Heiman G., Deng Z., Hen R., Hodge S.E., and Knowles J.A. Potential panic disorder syndrome: clinical and genetic linkage evidence. Am. J. Med. Genet. 96 (2000) 24-35
79. West M.J., and Gundersen H.J. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 296 (1990) 1-22
80. Zhang J.M., Dix J., Langtimm-Sedlak C.J., Trusk T., Schroeder B., Hoffmann R., Strosberg A.D., Winslow J.W., and Sieber-Blum M. Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine. J. Neurobiol. 32 (1997) 262-280